LT3141617T - Vėžio pasekmių prognozavimo pacientui būdai, analizuojant genų ekspresiją - Google Patents

Vėžio pasekmių prognozavimo pacientui būdai, analizuojant genų ekspresiją

Info

Publication number
LT3141617T
LT3141617T LTEP16193596.0T LT16193596T LT3141617T LT 3141617 T LT3141617 T LT 3141617T LT 16193596 T LT16193596 T LT 16193596T LT 3141617 T LT3141617 T LT 3141617T
Authority
LT
Lithuania
Prior art keywords
outcome
predicting
cancer
patient
methods
Prior art date
Application number
LTEP16193596.0T
Other languages
English (en)
Inventor
Jérôme GALON
Franck Pages
Bernard Mlecnik
Herve Fridman
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Université Paris Descartes
Assistance Publique Hôpitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique Hôpitaux De Paris filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of LT3141617T publication Critical patent/LT3141617T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
LTEP16193596.0T 2011-01-11 2012-01-11 Vėžio pasekmių prognozavimo pacientui būdai, analizuojant genų ekspresiją LT3141617T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305024 2011-01-11
US201161434514P 2011-01-20 2011-01-20

Publications (1)

Publication Number Publication Date
LT3141617T true LT3141617T (lt) 2019-02-25

Family

ID=43778393

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16193596.0T LT3141617T (lt) 2011-01-11 2012-01-11 Vėžio pasekmių prognozavimo pacientui būdai, analizuojant genų ekspresiją

Country Status (8)

Country Link
US (4) US20140018255A1 (lt)
EP (2) EP2663650B1 (lt)
JP (1) JP6505656B2 (lt)
DK (1) DK3141617T3 (lt)
ES (1) ES2609249T3 (lt)
LT (1) LT3141617T (lt)
PL (1) PL3141617T3 (lt)
WO (1) WO2012095448A1 (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2880180B1 (en) * 2012-08-06 2018-10-03 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and kits for screening patients with a cancer
US10720230B2 (en) 2017-06-13 2020-07-21 Bostongene Corporation Method for administering a checkpoint blockade therapy to a subject
WO2019010339A1 (en) 2017-07-05 2019-01-10 The Regents Of The University Of California DOSAGE FOR PREOPERATIVE PREDICTION OF RECOVERY OF AN ORGAN FUNCTION
JP2022536075A (ja) 2019-06-03 2022-08-12 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 処置レジメンを調節する方法
TW202132573A (zh) 2019-11-07 2021-09-01 美商昂克賽納醫療公司 腫瘤微環境之分類
EP4172628A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
JP2023531305A (ja) 2020-06-30 2023-07-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法後の固形癌患者の再発及び／又は死亡のリスクを予測するための方法。
WO2023175366A1 (en) 2022-03-17 2023-09-21 Veracyte Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773883B2 (en) * 2000-07-31 2004-08-10 The Brigham & Women's Hospital, Inc. Prognostic classification of endometrial cancer
US20050287544A1 (en) * 2003-12-01 2005-12-29 Francois Bertucci Gene expression profiling of colon cancer with DNA arrays
WO2005071419A2 (en) * 2004-01-16 2005-08-04 Ipsogen Protein expression profiling and breast cancer prognosis
US20080268476A1 (en) * 2004-05-12 2008-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (N4) as a Marker for Cancer Prognosis
JP4370409B2 (ja) * 2005-06-22 2009-11-25 国立大学法人東北大学 がんの予後予測方法
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
KR20080073745A (ko) * 2005-11-14 2008-08-11 바이엘 헬스케어 엘엘씨 암의 예측 및 예후 방법, 및 암 치료 요법을 모니터하는방법
CA2699434A1 (en) * 2006-09-15 2008-04-24 Mcgill University Stroma derived predictor of breast cancer
JP5773315B2 (ja) * 2008-11-27 2015-09-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 膵癌のバイオマーカーとしてのｃｘｃｌ４ｌ１
EP2213682A1 (en) * 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
WO2010144192A1 (en) * 2009-05-05 2010-12-16 Children's Medical Center Corporation Prognosis indicators for solid human tumors

Also Published As

Publication number Publication date
PL3141617T3 (pl) 2019-04-30
JP6051166B2 (ja) 2016-12-27
JP6505656B2 (ja) 2019-04-24
US20140018255A1 (en) 2014-01-16
JP2017060515A (ja) 2017-03-30
DK3141617T3 (en) 2019-02-25
WO2012095448A1 (en) 2012-07-19
ES2609249T3 (es) 2017-04-19
US20200248269A1 (en) 2020-08-06
EP3141617A3 (en) 2017-04-19
JP2014506782A (ja) 2014-03-20
US20150225799A1 (en) 2015-08-13
EP2663650B1 (en) 2016-11-09
US20170175207A1 (en) 2017-06-22
EP3141617B1 (en) 2018-11-14
EP2663650A1 (en) 2013-11-20
EP3141617A2 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
IL233709A (en) A method to predict the likelihood of clinical outcome for a patient with prostate cancer
EP2686689A4 (en) METHODS OF PREDICTING RISK OF UNDESIRABLE CLINICAL RESULT
HK1203091A1 (en) Methods for diagnosis of lung cancer
ZA201308111B (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP2768983A4 (en) METHODS OF IDENTIFYING MUTATIONS ASSOCIATED WITH DISEASES
IL229254A0 (en) Therapeutic antibodies
ZA201404655B (en) Methods for improving medical therapies
EP2720719A4 (en) METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS
LT3141617T (lt) Vėžio pasekmių prognozavimo pacientui būdai, analizuojant genų ekspresiją
EP2788752A4 (en) METHOD FOR SELECTING TREATMENT FOR PATIENTS SUFFERING FROM CANCER
GB201102014D0 (en) Method for predicting risk of developing cancer
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
HK1200195A1 (en) Product selection using genetic analysis
EP2707710A4 (en) DIAGNOSIS OF CANCER
GB2488349B (en) Location data analysis
GB201100282D0 (en) Biological methods
EP2685257A4 (en) METHOD OF ANALYSIS
IL228644A0 (en) Cancer treatment methods
EP2717901A4 (en) HE4-BASED THERAPY FOR MALIGNINE DISEASES
IL232493A0 (en) A method for quantifying cancer treatment
ZA201502595B (en) Therapeutic methods
EP2791843A4 (en) PROGRAMMABLE CELL MODEL FOR DETERMINING TREATMENTS AGAINST CANCER
EP2742358A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
EP2699699A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
EP2785870A4 (en) SMYD2 AS A TARGET GENE FOR ANTICANCER THERAPY AND THE DIAGNOSIS OF CANCER